Discussing Immunotherapy Options in Advanced Non–Clear Cell RCC
The program was brought together to discuss immunotherapy options for non–clear cell RCC in light of emerging clinical trial data and NCCN guidelines.
Related Articles
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
Gender equity in oncology: Progress, challenges, and the path forward in urologic oncology and oncologic specialties
Despite the increasing number of women in medicine, gender disparities in leadership and career advancement, particularly in oncology, remain prominent. Addressing issues such as pay…
How a stem cell transplant changed the life — and blood — of a leukemia patient
A stem cell donor changed Laura Tiberi’s life after her leukemia diagnosis. Now she’s sharing hope and inspiration with other transplant recipients.
New Tool Can Help Improve Health Equity in Cancer Centers : Oncology Times
An abstract is unavailable.
Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer
The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.
Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to…
Fox Chase Honors Those Touched by Cancer with 2024 Tree of Life Celebration
Every holiday season, Fox Chase Cancer Center’s Tree of Life Celebration brings together patients, families, donors, researchers, and medical staff to pay tribute to all…
FDA Grants Priority Review to Sunvozertinib in EGFR+ NSCLC
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on promising efficacy and safety data…